The Journal of Immunology, Vol 154, Issue 4 1909-1918, Copyright © 1995 by American Association of Immunologists

ARTICLES

Growth hormone is a human macrophage activating factor. Priming of human monocytes for enhanced release of H2O2

J Warwick-Davies, DB Lowrie and PJ Cole
Host Defense Unit, Royal Brompton National Heart and Lung Institute, London, United Kingdom.

Although many effects of growth hormone (GH) and related factors upon the immune system have been demonstrated, few studies have examined the capacity of these factors to modulate human monocyte function in vitro. Assaying a range of mediators, only GH and prolactin (PRL), at 0.3 to 1.0 micrograms/ml, and growth hormone-releasing hormone (GRH) at very high doses, primed monocytes for enhanced hydrogen-peroxide production (H2O2) in response to PMA. GH-induced priming was not caused by endotoxin, nor by production of lymphokines such as IFN-gamma. Exogenous insulin-like growth factor-I (IGF-I), alone or in combination with GH, was without effect, making it unlikely that GH mediates its effects on monocytes via an autocrine/paracrine action of IGF-I. Monocytes specifically bound radiolabeled GH and contained mRNA for the GH receptor and, in some donors, the PRL receptor. Therefore, GH probably exerts its effects as a human macrophage-activating factor through either GH or PRL receptors, without requiring production of IGF- I.

This article has been cited by other articles:

				C. Grasemann, F. Ratjen, D. Schnabel, E. Reutershahn, U. Vester, and H. Grasemann Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients Eur. Respir. J., April 1, 2008; 31(4): 815 - 821. [Abstract] [Full Text] [PDF]

				R. Campos-Rodriguez, A. Quintanar-Stephano, R. A. Jarillo-Luna, G. Oliver-Aguillon, J. Ventura-Juarez, V. Rivera-Aguilar, I. Berczi, and K. Kovacs Hypophysectomy and Neurointermediate Pituitary Lobectomy Reduce Serum Immunoglobulin M (IgM) and IgG and Intestinal IgA Responses to Salmonella enterica Serovar Typhimurium Infection in Rats Infect. Immun., March 1, 2006; 74(3): 1883 - 1889. [Abstract] [Full Text] [PDF]

				S. Pagani, C. Meazza, P. Travaglino, F. De Benedetti, C. Tinelli, and M. Bozzola Serum cytokine levels in GH-deficient children during substitutive GH therapy Eur. J. Endocrinol., February 1, 2005; 152(2): 207 - 210. [Abstract] [Full Text] [PDF]

				Z. Liu, Y. Yu, Y. Jiang, and J. Li Growth Hormone Increases Lung NF-{kappa}B Activation and Lung Microvascular Injury Induced by Lipopolysaccharide in Rats Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 164 - 170. [Abstract] [Full Text] [PDF]

				S. H. Zarkesh-Esfahani, O. Kolstad, R. A. Metcalfe, P. F. Watson, S. Von Laue, S. Walters, A. Revhaug, A. P. Weetman, and R. J. M. Ross High-Dose Growth Hormone Does Not Affect Proinflammatory Cytokine (Tumor Necrosis Factor-{alpha}, Interleukin-6, and Interferon-{gamma}) Release from Activated Peripheral Blood Mononuclear Cells or after Minimal to Moderate Surgical Stress J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3383 - 3390. [Abstract] [Full Text]

				K. Dorshkind and N. D. Horseman The Roles of Prolactin, Growth Hormone, Insulin-Like Growth Factor-I, and Thyroid Hormones in Lymphocyte Development and Function: Insights from Genetic Models of Hormone and Hormone Receptor Deficiency Endocr. Rev., June 1, 2000; 21(3): 292 - 312. [Abstract] [Full Text]

				J. Takala, E. Ruokonen, N. R. Webster, M. S. Nielsen, D. F. Zandstra, G. Vundelinckx, and C. J. Hinds Increased Mortality Associated with Growth Hormone Treatment in Critically Ill Adults N. Engl. J. Med., September 9, 1999; 341(11): 785 - 792. [Abstract] [Full Text] [PDF]

				W. Liao, M. Rudling, and B. Angelin Contrasting Effects of Growth Hormone and Insulin-Like Growth Factor I on the Biological Activities of Endotoxin in the Rat Endocrinology, January 1, 1997; 138(1): 289 - 295. [Abstract] [Full Text] [PDF]